Kodiak Sciences Inc. has released its financial results for the second quarter of 2025, revealing a net loss of $54.3 million, or $1.03 per share, compared to a net loss of $45.1 million, or $0.86 per share, in the same period of 2024. The company's cash position at the end of the second quarter stood at $104.2 million, which is expected to support operations into 2026. Research and development expenses for the quarter increased to $42.8 million from $32.5 million in the previous year, primarily due to heightened clinical activities related to the APEX, DAYBREAK, and GLOW2 studies. The quarter's R&D expenses included $7.7 million in non-cash stock-based compensation, down from $8.9 million in the second quarter of 2024. Kodiak Sciences also highlighted recent business developments, including promising new data from the KSI-101 APEX Phase 1b study, which underscores its potential in treating macular edema secondary to inflammation. Looking ahead, the company anticipates topline data from the Phase 3 study of its asset, tarcocimab, in the first and third quarters of 2026.